Oct 30 (Reuters) - Avidity Biosciences Inc :
* AVIDITY BIOSCIENCES PURSUES POTENTIAL ACCELERATED APPROVAL PATH WITH INITIATION OF BIOMARKER COHORT IN FORTITUDE™ TRIAL FOR DELPACIBART BRAXLOSIRAN (DEL-BRAX/AOC 1020) IN PEOPLE LIVING WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
* AVIDITY BIOSCIENCES: ENROLLMENT IN DEL-BRAX BIOMARKER COHORT EXPECTED TO BE COMPLETED IN 1H 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.